Skip to content

Study · Animal study (in vivo) · rat · 2019

4 results

Linaclotide treatment reduces endometriosis-associated vaginal hyperalgesia and mechanical allodynia through viscerovisceral cross-talk.

Ge P, Ren J, Harrington AM, Grundy L, Castro J, Brierley SM, Hannig G

Pain1 Nov 2019Cited by 31 (Europe PMC)

PMID31335750 (opens in a new tab)DOI10.1097/j.pain.0000000000001657 (opens in a new tab)PepBankPUB-31335750
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with endometriosis, daily oral linaclotide increased vaginal distension pain thresholds relative to vehicle.

    In plain wordsIn rats with endometriosis, linaclotide increased vaginal pain thresholds compared with vehicle.

    Peptide
    Linaclotide
    Outcome
    IncreaseVaginal distension pain threshold
    Study

    ratn: not reported in source

    Endometrium transplantation model of endometriosis
    Comparator
    Vehicle
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · oralAs given in this study (rat).

    Source sentences

    Summary
    Daily oral administration of linaclotide, a peripherally restricted guanylate cyclase-C (GC-C) agonist peptide acting locally within the gastrointestinal tract, increased pain thresholds to vaginal distension and mechanical hind paw withdrawal thresholds relative to vehicle treatment.
    1 context sentence
    Summary · context
    Here, we investigated the effects of linaclotide, a Food and Drug Administration-approved treatment for IBS-C, in a rat model of endometriosis.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with endometriosis, daily oral linaclotide increased mechanical hind paw withdrawal thresholds relative to vehicle.

    In plain wordsIn rats with endometriosis, linaclotide increased hind paw withdrawal thresholds compared with vehicle.

    Peptide
    Linaclotide
    Outcome
    IncreaseMechanical hind paw withdrawal threshold
    Study

    ratn: not reported in source

    Endometrium transplantation model of endometriosis
    Comparator
    Vehicle
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · oralAs given in this study (rat).

    Source sentences

    Summary
    Daily oral administration of linaclotide, a peripherally restricted guanylate cyclase-C (GC-C) agonist peptide acting locally within the gastrointestinal tract, increased pain thresholds to vaginal distension and mechanical hind paw withdrawal thresholds relative to vehicle treatment.
    1 context sentence
    Summary · context
    Here, we investigated the effects of linaclotide, a Food and Drug Administration-approved treatment for IBS-C, in a rat model of endometriosis.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with endometriosis, switching from vehicle to linaclotide increased hind paw withdrawal thresholds.

    In plain wordsIn rats with endometriosis, hind paw withdrawal thresholds increased after linaclotide replaced vehicle.

    Peptide
    Linaclotide
    Outcome
    IncreaseHind paw withdrawal threshold after switching to linaclotide
    Study

    ratn: not reported in source

    Endometrium transplantation model of endometriosis
    Comparator
    Previous vehicle treatment
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · oralAs given in this study (rat).

    Source sentences

    Summary
    Furthermore, using a cross-over design, administering linaclotide to rats previously administered vehicle resulted in increased hind paw withdrawal thresholds, whereas replacing linaclotide with vehicle treatment decreased hind paw withdrawal thresholds.
    1 context sentence
    Summary · context
    Here, we investigated the effects of linaclotide, a Food and Drug Administration-approved treatment for IBS-C, in a rat model of endometriosis.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with endometriosis, replacing linaclotide with vehicle decreased hind paw withdrawal thresholds.

    In plain wordsIn rats with endometriosis, hind paw withdrawal thresholds decreased after vehicle replaced linaclotide.

    Peptide
    Linaclotide
    Outcome
    DecreaseHind paw withdrawal threshold after linaclotide withdrawal
    Study

    ratn: not reported in source

    Endometrium transplantation model of endometriosis
    Comparator
    Previous linaclotide treatment
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · oralAs given in this study (rat).

    Source sentences

    Summary
    Furthermore, using a cross-over design, administering linaclotide to rats previously administered vehicle resulted in increased hind paw withdrawal thresholds, whereas replacing linaclotide with vehicle treatment decreased hind paw withdrawal thresholds.
    1 context sentence
    Summary · context
    Here, we investigated the effects of linaclotide, a Food and Drug Administration-approved treatment for IBS-C, in a rat model of endometriosis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.